Anxiety, palpitations, dyspnoea, sweating and irritability are common symptoms in pregnant women. If a goitre is also present, the possibility of hyperthyroidism must be considered. An increased sleeping pulse rate, failure to gain weight or more especially weight loss, provide compelling clinical evidence for this diagnosis. Intractable vomiting may also occur and be misinterpreted as 'hyperemesis gravidarum'1. In most cases, however, the clinical suspicion will not be confirmed because hyperthyroidism in pregnancy is rare; in the writer's experience, at the three Dublin maternity hospitals the prevalence during the years 1979-1985 was 0.05% in more than 150 000 deliveries.
When clinical suspicion is aroused, the diagnosis must be confirmed or refuted by biochemical tests of thyroid function, which must be interpreted with caution.
In order to understand the diagnostic and therapeutic problems posed, it is necessary to appreciate the adaptive changes in maternal thyroid function which occur in pregnancy and the interrelationships between mother, placenta and fetus.
From an early stage there is an increase in the renal excretion of iodide with a corresponding fall in plasma levels2. In response, thyroidal trapping of iodide is increased and unless there is a liberal supply in the diet, thyroid size increases so that goitre is common. Thus, in north-east Scotland 74% of pregnant women had a goitre3, while in Dublin the prevalence was 58% (unpublished observation). There are associated changes in the biochemical tests ofthyroid function. With increasing production of oestrogen by the placenta there is an increase in the hepatic synthesis of thyroxine-binding globulin (TBG) and as a result the serum levels oftotal T4 and T3 increase with a reciprocal reduction in resin uptake. During pregnancy, therefore, the results of conventional biochemical tests will be in the hyperthyroid range, so that free hormone levels must be used as true indices of function. Even then the results should be interpreted with caution, as in normal pregnancy free hormone levels may also be slightly elevated because of the relative saturation of TBG and the increased serum thyroid-stimulating hormone activity secondary to the production of placental chorionic gonadotrophin.
Accurate diagnosis is important because untreated hyperthyroidism is associated with increased fetal loss4, with premature labour5, and with low birth weight6. Conversely, the prescription of antithyroid drugs in a euthyroid woman would obviously be harmful.
Fortunately, in many cases diagnosis is not a problem as this will have been made and treatment instituted before conception. In such cases the antithyroid drugs may be continued without fear of teratogenicity, although dosage adjustments may be required (see below). If the diagnosis is made for the first time during pregnancy, antithyroid drugs are the appropriate form of treatment. Radioiodine therapy is obviously contraindicated and whilst surgery is an option it should be reserved for exceptional cases, e.g. drug intolerance or non-compliance.
Three groups ofdrugs have been usedthiouracils (methyl or propyl), imidazoles (methimazole and carbimazole) and beta-adrenergic blockers (e.g. propranolol). All cross the placenta and may interfere with fetal thyroid function which matures independently of the mother. For this reason there was a vogue to add thyroxine to the regimen in the belief that this would protect the fetus from goitre and hypothyroidism, but as the placenta is impermeable to thyroxine this practice had no merit. Concern for fetal thyroid function also led to the suggestion that the dose of antithyroid drugs should be kept to a minimum but, in fact, there is no direct correlation between dosage and the occurrence of fetal goitre. In this context the convention of stopping treatment at 37 or 38 weeks (except in the newly diagnosed who might relapse quickly) may not be necessary either, as in our series 27 patients delivered whilst still taking carbimazole without any neonatal problems. Neither may it be necessary to forbid breast feeding when treatment is resumed after delivery, provided that dosage is small7. Propranolol antagonizes the sympathomimetic influence of thyroxine and diverts T4 to the rT3 pathway. Although patients have been successfully treated with this drug8, there have been accounts of fetal bradycardia, ofintrauterine growth retardation and of hypoglycaernia and depressed respiration in the neonate in association with maternal ingestion of propranolol9l10. Beta-adrenergic blockers should therefore be reserved for short-term use, e.g. to control severe tachycardia whilst awaiting the effects of the antithyroid drug or in a thyroid crisis.
Based on paper read to Section of Endocrinology, 22 May 1985 Our policy is to use carbimazole alone. Patients who have been on treatment before conception are continued on their maintenance dose, which is usually 5-10mg daily. In those diagnosed during pregnancy, the initial dose is 15 mg four times daily with stepwise reduction at intervals of 4 weeks to a daily maintenance dose of 5-10 mg. Response is assessed by control of symptoms, by reduction in pulse rate and increase in body weight; measurements of free hormone levels may be comforting but are rarely needed.
In properly managed cases the outcome is extremely good. In a personal series of 140 cases the overall fetal loss was 14%. There were 4 perinatal deaths (3.2%). During the same time period the average perinatal loss for all patients in the three hospitals was 2.5%. Goitre occurred in 4 infants (3.2%). Of these one had neonatal thyrotoxicosis, one had permanent hypothyroidism, one had transient hypothyroidism and one was stillborn.
All neonates should be examined for goitre and thyroid dysfunction. Although neonatal thyrotoxicosis is rare (1-2%), it is important to realize that it may occur in the fetus or neonate of any woman who has or has had hyperthyroidism irrespective of her current thyroid status. Even in a euthyroid mother, active thyrotrophic receptor antibodies may persist in the circulation and cross the placenta. If the mother is on an antithyroid drug, the effect of the stimulating antibody will be nullified; but if she is not, the persisting antibody may cause intrauterine 0141-0768/86/ 060317-02/$02.00/0 ) 1986 The Royal Society of Medicine hyperthyroidism'0, which should be suspected if there is fetal tachycardia in excess of 160 per minute. A high titre of thyroid-stimulating immunoglobulins in the mother makes the diagnosis likely. Administration of antithyroid drugs to the mother in low dosage controls the fetal hyperthyroidism' 1,12. The thyroid status, physical and psychological development of 43 children born to mothers treated with antithyroid drugs has been assessed at followup periods varying from 1 to 13 years in three series'3 -15 and there was no evidence of untoward effects. The long-term effects of neonatal hyperthyroidism may not be so benign. Of 74 children studied by Hollingsworth et al." 6, 9 (35%) were still hyperthyroid beyond the first year of life, 7 (27%) had psychomotor abnormalities and 11 (42%) had some retardation of skeletal growth.
Hyperthyroidism may occur with hydatidiform mole and choriocarcinoma. Biochemical abnormalities are more common than clinical hyperthyroidism, which must be rare as no cases were seen in 53 molar pregnancies which occurred among 83 733 mothers (0.06%)delivered at the National Maternity Hospital, Dublin, during the decade 1971-1980. A bioassayable thyroid stimulator has been demonstrated in patients' sera and in molar tissue. This may be identical with human chorionic gonadotrophin, which has intrinsic thyrotrophic activity. Variations in biological potency may explain the varying degrees of thyroid dysfunction which is. corrected by evacuation of molar tissue.
Very occasionally hyperthyroidism presents within 3 months ofdelivery. Some of these cases may represent previously unrecognized Graves' disease, but rarely they are due to the initial transient overactive phase of autoimmune thyroiditis. The clue to this diagnosis is the paradoxical combination of an elevated serum thyroxine and low radioiodine uptake.
